https://doi.org/10.71450/45513910
Published: 16/02/2024
Peer reviewed by two members of Breast Cancer UK independent Science Panel.
Hormone replacement therapy (HRT) is used to manage the symptoms of menopause. It has been associated with an increased risk of developing breast cancer; however, this risk varies according to the type of HRT and duration of use. Evidence suggests that oestrogen-only HRT has little to no increased risk of breast cancer; however, it is generally only prescribed to people who have had a hysterectomy as it carries an increased risk of uterine cancer. Combined HRT is associated with a duration-dependent increase in breast cancer risk when used over five years. This increase in risk then reduces after combined HRT treatment is stopped, but some risk remains if used for over 10 years. To date, HRT is considered the most effective approach for managing menopausal symptoms. The decision on whether to take HRT should be an individual choice, made in consultation with a specialist healthcare practitioner based on personal symptoms, risks, benefits, treatment suitability and duration.
Boulin T., Whitcroft I., Moody H. HRT, menopause and breast cancer Breast Cancer UK. 2024. https://doi.org/10.71450/45513910
Next update: 16/02/2027
